Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of [14C]-Famitinib in Healthy Men
NCT05473468Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of famitinib in solid tumor, sponsored by Hengrui. Primary endpoints: Mass balance recovery of total radioactivity in all excreta urine: CumAe and Cum%Ae, Mass balance recovery of total radioactivity in all excreta feces: CumAe and Cum%Ae and 8 more. Status: unknown.
02
Drugs
famitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05473468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473468.